For research use only. Not for therapeutic Use.
ADS032 is a dual inhibitor of NLRP1 and NLRP3 that can rapidly, reversibly and stably inhibit inflammasome formation. ADS032 can reduce NLPR1 and NLRP3 activation of human macrophages and bronchial epithelial cells to secrete and mature IL-1β and TNF-α, and reduce NLRP3-induced ASC speck formation. ADS032 protected mice against the deadly influenza A virus, reducing inflammation in the lungs and improving survival. ADS032 inhibits Nigericin (HY-127019)-induced IL-1β secretion with IC50s of 94.6 μM (No wash out) and 354 μM (Wash out) respectively[1].
| Catalog Number | I040540 |
| CAS Number | 2757333-37-0 |
| Synonyms | 4-[4-[4-(dipropylsulfamoyl)phenyl]phenyl]butanoic acid |
| Molecular Formula | C22H29NO4S |
| Purity | ≥95% |
| InChI | InChI=1S/C22H29NO4S/c1-3-16-23(17-4-2)28(26,27)21-14-12-20(13-15-21)19-10-8-18(9-11-19)6-5-7-22(24)25/h8-15H,3-7,16-17H2,1-2H3,(H,24,25) |
| InChIKey | UNMDICXGCNPMPK-UHFFFAOYSA-N |
| SMILES | CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)CCCC(=O)O |
| Reference | [1]. Docherty CA, et al. A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases. Clin Transl Immunology. 2023 Jun 22;12(6):e1455. |
